Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) Accumulated Depreciation & Amortization (2020 - 2025)

Historic Accumulated Depreciation & Amortization for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $5.7 million.

  • Cytek Biosciences' Accumulated Depreciation & Amortization rose 606.57% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 606.57%. This contributed to the annual value of $7.2 million for FY2024, which is 1924.6% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Accumulated Depreciation & Amortization is $5.7 million, which was up 606.57% from $3.8 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Accumulated Depreciation & Amortization high stood at $7.2 million for Q4 2024, and its period low was $1.0 million during Q1 2023.
  • Its 5-year average for Accumulated Depreciation & Amortization is $3.1 million, with a median of $2.4 million in 2022.
  • Data for Cytek Biosciences' Accumulated Depreciation & Amortization shows a peak YoY increase of 15517.04% (in 2023) and a maximum YoY decrease of 5454.13% (in 2023) over the last 5 years.
  • Over the past 5 years, Cytek Biosciences' Accumulated Depreciation & Amortization (Quarter) stood at $1.2 million in 2021, then surged by 100.64% to $2.5 million in 2022, then soared by 142.7% to $6.0 million in 2023, then increased by 19.25% to $7.2 million in 2024, then fell by 21.2% to $5.7 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $5.7 million for Q3 2025, versus $3.8 million for Q2 2025 and $1.9 million for Q1 2025.